Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.

Participants must have HER2-low and PD-L1 positive （CPS≥1）breast cancer that has been treated before.

Participants' cancer:

Cannot be removed by an operation Has spread to other parts of the body
Breast Cancer
DRUG: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
Progression-free survival(PFS), Time from treatment until disease progression or death, 2 years
Objective Response Rate（ORR）, Objective Response Rate（ORR）by RECIST 1.1,the total proportion of patients with complete response（CR）, partial response（PR）, 2 years|Clinical Benefit Rate (CBR), the total proportion of patients with Partial Response (PR), Complete Response (CR) or Stable Disease (SD) ≥6 months, 2 years|Disease Control Rate （DCR）, the total proportion of patients with complete response（CR）, partial response（PR）and stable disease（SD）, 2 years|Overall survival (OS), Time from treatment until death from any cause, 2 years
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.

Participants must have HER2-low and PD-L1 positive （CPS≥1）breast cancer that has been treated before.

Participants' cancer:

Cannot be removed by an operation Has spread to other parts of the body